Journal
DIABETIC MEDICINE
Volume 30, Issue 3, Pages 289-299Publisher
WILEY
DOI: 10.1111/j.1464-5491.2012.03746.x
Keywords
-
Categories
Funding
- Karl und Lore Klein-Stiftung
- German Heart Foundation/German Foundation of Heart Research
- Ernst und Berta Grimmke-Stiftung
- Deutsche Forschungsgemeinschaft [MA 2047 4-1]
- European Foundation for the Study of Diabetes
- Novartis-Stiftung fur therapeutische Forschung
- Boerhinger Ingelheim
- Merck Sharp and Dohme
Ask authors/readers for more resources
Diabet. Med. 30, 289299 (2013) Abstract Aims Glucagon-like peptide-1 receptor agonists and inhibitors of dipeptidyl peptidase-4 that increase glucagon-like peptide-1 plasma concentrations are current treatment options for patients with diabetes mellitus. As patients with diabetes are a high-risk population for the development of a severe and diffuse atherosclerosis, we aim to review the potential action of these drugs on cardiovascular disease and to summarize the potential role of present glucagon-like peptide-1-based therapies from a cardiologist's point of view. Methods Using a PubMed/MEDLINE search without language restriction, studies were identified and evaluated in order to review the effects of glucagon-like peptide-1-based therapy on different stages of the cardiovascular continuum. Results Recent experimental as well as clinical data suggest that dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonistsin addition to their metabolic effectsmay have beneficial effects on the cardiovascular continuum at multiple stages, including: (1) cardiovascular risk factors; (2) molecular mechanisms involved in atherogenesis; (3) ischaemic heart disease; and (4) heart failure. Furthermore, retrospective analysis suggested decreased cardiovascular events in patients with glucagon-like peptide-1-based therapies. Conclusion There are ample data to suggest beneficial effects of glucagon-like peptide-1-based therapies on the cardiovascular continuum and large-scale clinical trials are warranted to determine whether these effects translate into improved cardiovascular endpoints in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available